Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
NCT06968975
Recruiting
This study is an observational, ambispective, descriptive, non-interventional study of people with a chronic inflammatory demyelinating polyneuropathy/polyradiculoneuropathy (CIDP) diagnosis in the United States with residual impairment, disability, or neurological deficits after at least three months of treatment with standard of care therapy. The study is expected to last two years. Enrollment is expected to continue for one year. Depending on when the participant is enrolled, a participant ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Investigational Site, Swiftwater, Pennsylvania
Conditions: Polyneuropathy, Inflammatory Demyelinating, Chronic
Register for Updates
Development and Validation of Virtual Laparoscopic Hiatal Hernia Simulator
NCT06974383
Recruiting
The goal of this study is to establish the face, content, discriminant and predictive validity of the Virtual Laparoscopic Hiatal Hernia Simulator (VLaHHS). The study population includes GS residents. The goal of developing scenarios for the simulator will be accomplished first and establishing the validity of the VLaHHS will be conducted in three phases after that: 1. Needs assessment survey of current practices in laparoscopic hiatal hernia repair a. Development of scenarios and metrics for... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/25/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Predictive Validity of VLaHHS
Register for Updates
Assessment of Tubal Occlusion During Minimally Invasive Myomectomy
NCT06988774
Recruiting
This study uses a procedure called chromopertubation to look at how fibroids and fibroid surgery affect the fallopian tubes. Specifically, this study will test if the fallopian tubes are occluded or patent (open) before and after surgically removing fibroids. Chromopertubation is a commonly performed and well-established procedure that is done during laparoscopic surgery to determine if the fallopian tubes are open or blocked. It includes inserting a dilute solution of saline with a small amoun... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Fallopian Tube Patency Tests, Fibroid/Myoma (Uterus/Cervix), Myomectomy, Fallopian Tube Disease
Register for Updates
E-Tailored Pain Management Support for Dementia Family Caregivers: Feasibility of the PACE-app
NCT07032350
Recruiting
The goal of this clinical trial is to test whether a web-based application called the Pain Control Enhancement App (PACE-app) can support family caregivers in managing pain for their care recipients with dementia. The main questions it aims to answer are: Is it feasible and acceptable for family caregivers to use the PACE-app? Does using the PACE-app improve caregiver self-efficacy in pain management, adherence to pain treatments, communication with care providers, well-being, and their care r... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/25/2025
Locations: College of Nursing, Iowa City, Iowa
Conditions: Care Giving Burden, Dementia, Chronic Pain, Pain Management, Palliative Care
Register for Updates
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
NCT07033026
Recruiting
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: NGM Clinical Study Site, Laredo, Texas
Conditions: Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia
Register for Updates
Integrated Telemedicine Program Evaluation
NCT07042477
Recruiting
This project will evaluate a virtual, on-demand telemedicine program for High emergency department (ED) utilizers with comorbid physical health conditions and behavioral health correlates. Researchers will randomize patients to have either full access to the full intervention (treatment group) or to receive only standard care (control group). Analyses will be intent-to-treat. The primary outcome is the number of ED visits 120 days after the first Best Practice Alert (BPA) firing. The research t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Geisinger Clinic, Danville, Pennsylvania
Conditions: Behavioral Intervention, Emergency Department Visits, Telemedicine
Register for Updates
Healthy Family Project: Tobacco Use and Smoke Exposure in Asian American Communities
NCT07049757
Recruiting
This study evaluates whether the Smokefree Family Living (SFL) intervention improves quit rates (smoking cessation) and exposure to tobacco contamination that stays in items such as, carpets, walls, and furniture, even after the smoke has cleared (third-hand smoke (THS)) among Chinese American smokers and their non-smoking household members. Smoking remains high among Chinese American males with limited ability to speak English. This causes the non-smoking household members to be exposed to THS,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Tobacco-Related Carcinoma, Smoking Cessation
Register for Updates
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
NCT07051629
Recruiting
This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/25/2025
Locations: Accel Research sites network, DeLand, Florida +1 locations
Conditions: Epilepsy, Healthy Volunteer
Register for Updates
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
NCT00412594
Recruiting
This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
Register for Updates
Registry of Older Patients With Cancer
NCT01137825
Recruiting
RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
06/24/2025
Locations: Seby B. Jones Cancer Center, Boone, North Carolina +6 locations
Conditions: Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
NCT01639508
Recruiting
The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity. A phase II study looks at how effective a medication is at treating a specific type of cancer and collects information on the side effects of the study treatment. RET, ROS1, or NTRK fusion or increased MET or AXL activity gene leads to lung cancer cell growth. Cabozantini... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02523014
Recruiting
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +768 locations
Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Register for Updates